Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating activities:
Net (loss) income	$ (33,867)	$ 5,285	$ (67,138)
Adjustments to reconcile net (loss) income to net cash flows used in operating activities
Depreciation	740	693	437
Accretion of debt discount and loan costs	4,138	2,392	397
Amortization of intangible assets	5,157	5,425	971
(Recovery from) provision for inventory obsolescence	(56)	243
Impairment loss on equipment	78
Stock-based compensation expense	5,941	14,801	14,931
Deferred income taxes	40	(15,972)
Bargain purchase gain		(27,336)
Changes in assets and liabilities, net of effect of acquisition:
Accounts receivable	(4,640)	(5,884)	(862)
Inventories	741	2,448	(810)
Prepaid expenses and other assets	422	526	(203)
Accounts payable and accrued expenses	(2,807)	6,644	(1,546)
Deferred revenue		(21,716)	(159)
Net cash flows used in operating activities	(24,113)	(32,451)	(53,982)
Investing activities:
BELBUCA acquisition	(1,951)	(5,853)
Purchase of equipment	(112)	(11)	(405)
Net cash flows used in investing activities	(2,063)	(5,864)	(405)
Financing activities:
Proceeds from sales of securities, net of costs incurred			40
Proceeds from exercise of stock options	670	439	297
Issuance of common stock			2,460
Issuance of warrants			49
Proceeds from issuance of Series B preferred stock	50,000
Payment on note payable		(30,000)
Proceeds from notes payable		60,000
Equity finance costs	(1,417)
Payment of deferred financing fees	(450)	(2,948)
Net cash flows from financing activities	48,803	27,491	2,846
Net change in cash and cash equivalents	22,627	(10,824)	(51,541)
Cash and cash equivalents at beginning of year	21,195	32,019	83,560
Cash and cash equivalents at end of year	43,822	21,195	32,019
Cash paid for interest	6,053	5,285	$ 2,870
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings	$ 12,500
Common stock issuance upon retirement, shares	2,119,925
Common stock issuance upon retirement	$ 5,300
Fair value of bargain purchase price of BELBUCA acquisition		27,300
Fair value of warrants, in connection with CRG term loan		$ 6,000
Series B Non-Voting Convertible Preferred Stock [Member]
Non-cash Financing and Investing Activities:
Adjustments to additional paid in capital dividends in excess of retained earnings	12,500
Accrued financing expenses	$ 600